The View Hospital performs ME's1st magnetic surgery in pvt sector
Doha
The View Hospital, in affiliation with Cedars-Sinai, has announced the successful completion of the first magnetic duodenal-ileostomy procedure in the private sector in the Middle East. This groundbreaking revision surgery offers a solution for patients who have experienced weight regain following sleeve gastrectomy.
The advanced, minimally invasive procedure was performed by Dr Jassim Fakhro, Consultant in Metabolic and Bariatric Surgery and Medical Director of Qatari Physicians at The View Hospital, in the presence of Prof Michel Gagner, a global pioneer in metabolic surgery and the inventor of the magnetic technique.
Unlike conventional surgical approaches that require cutting or stapling, magnetic duodenal-ileostomy involves placing two rare-earth magnets into the small intestine — one in the duodenum and the other in the ileum. Over the course of a few days, the magnets gradually compress the tissue between them to form a secure, suture-free connection. This rerouting of the digestive tract enhances hormonal responses that regulate appetite and metabolism, supporting long-term weight loss while reducing the risks and recovery time associated with traditional surgery.
'Bariatric surgery has long been the most reliable and effective way we have for treating the severe obesity. Now, with the successful use of magnetic anastomosis we can lower the risk of complications like bleeding and leakage. Our most effective operations for the treatment of obesity are now safer than ever thanks to magnetic compression anastomosis,' said Dr Jassim Fakhro.
'We are proud to be the first private hospital in Qatar to experience this transformative platform. As a health system dedicated to remaining at the forefront of medical technology and innovation, we are excited about adopting this innovation to advance patient outcomes at The View Hospital,' said Dr Fatih Mehmet Gul, CEO of The View Hospital.
The successful procedure highlights The View Hospital's ongoing mission to bring world-class surgical innovation to Qatar. By being the first private healthcare provider in the country to adopt this technology, the hospital continues to set new benchmarks in bariatric and metabolic care, expanding its leadership in minimally invasive and patient-centred solutions.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Qatar Tribune
4 days ago
- Qatar Tribune
Veterinary quarantine facilities at Ruwais Port and Hamad Port receive 3-star GSAS certification
Tribune News Network Doha The new veterinary quarantine facilities at Ruwais Port and near Hamad Port have received three-star ratings from the Global Sustainability Assessment System (GSAS). This achievement is a culmination of Qatar's efforts to consolidate environmental sustainability practices within its various development projects, in line with the Qatar National Vision 2030 and its goals to promote green infrastructure. This achievement reflects the Ministry of Municipality's commitment to applying the highest sustainability standards in the design, construction, and operation of veterinary facilities, ensuring a healthy and safe environment and enhancing operational efficiency in accordance with international best practices. The GSAS system is the first integrated sustainability assessment system in the Middle East and North Africa region. It was specifically designed to align with the nature of the region's urban environment. It is the same system used to assess major projects such as the FIFA World Cup Qatar 2022 stadiums and Lusail City. This classification enhances the role of veterinary quarantines in supporting sustainable development goals and enhancing the efficiency of environmental infrastructure across the country. The Ministry of Municipality continues its efforts to enhance the efficiency of veterinary quarantines and expand their operational capabilities, as part of its strategy to develop service infrastructure to serve food security goals and protect society from trans-boundary animal diseases.
Qatar Tribune
6 days ago
- Qatar Tribune
AFC honours Dr Al Khulaifi with Medical Excellence Award
AFC Kuala Lumpur In a new achievement for the Qatar Football Association (QFA) and Aspetar, Orthopaedic and Sports Medicine Hospital, Dr. Khalid Abdulrahman Yousef Al Khulaifi, Consultant Orthopaedic and Sports Medicine Surgeon and Director of the Visiting Surgeons Program at Aspetar, representing the QFA, received the prestigious Asian Football Confederation (AFC) Medical Excellence Award during a ceremony held on the sidelines of the 8th AFC Medical Conference 2025, currently being held inKuala Lumpur. The award ceremony was attended by AFC leaders, the Malaysian Minister of Youth and Sports, and a number of invited medical experts from the region. The annual award is given to young medical talents under the age of 45, in recognition of their outstanding achievements in the fields of scientific research, the development of medical services, and the enhancement of professional training programs in football. This award is one of the most prominent honors granted by the AFC, having been first launched at the AFC Congress in India in 2015. It continued to celebrate young medical talents in China (2019), and will continue until the eighth edition in Malaysia in 2025. It aims to highlight the pivotal role of young doctors in supporting and developing football in the medical and research fields. The international honour bestowed represents a high-level recognition of Dr. Khalid Al Khelaifi's distinguished career in the field of sports medicine, and consolidates the leadership of Qatari medical talents on the continental and global arenas. His continued research, innovation, and training reflect absolute dedication and continuous giving in the service of sports and medicine. Khalid Ali Al Mawlawi, Acting Director of Aspetar, said, 'We congratulate Dr. Khalid Al Khulaifi on the remarkable achievement, which fills us with pride here at Aspetar. This recognition confirms the pioneering role played by Aspetar's staff in reaching the highest levels and achieving excellence on the regional and global levels. 'Dr. Al Khelaifi's winning of this award consolidates the leadership of Qatari medical competencies on the continental and global levels. It reflects the efforts exerted in serving sports and medicine, and motivates us all to continue in line with the hospital's vision of leadership.' Dr. Khalid Al Khelaifi expressed his happiness at winning the award, saying: 'The honour is the result of blessed efforts, thanks first to God, and then to the support of Aspetar Hospital, which provided me with the ideal environment for development and innovation, and the Qatar Football Association, which was a strong supporter. This achievement confirms the true brilliance of Qatari medical personnel, who are now capable of competing and excelling at the international level. 'I do not consider this victory a final milestone, but rather a strong push to continue the path of development and excellence in the field of sports medicine, and to serve sports not only in our beloved region, but also on the global level.' Dr. Khalid Al Khelaifi has previously served as Medical Director for the FIFA World Cup Qatar 2022, in addition to heading a number of medical committees as Sports Director, such as the 2023 Asian Cup and the Asian Youth Cup, in addition to numerous sports tournaments held in Qatar.
Qatar Tribune
23-07-2025
- Qatar Tribune
Sidra Medicine contributes to breakthrough tool for early detection of Type 1 diabetes
Tribune News Network Doha Sidra Medicine, a member of Qatar Foundation, has helped develop an artificial intelligence (AI) powered tool that predicts the risk of developing Type 1 Diabetes (T1D), enabling earlier diagnosis and more targeted care. The tool uses microRNA signals in the blood to detect early biological changes linked to the disease. Published in Nature Medicine, the study titled 'A microRNA-based dynamic risk score for type 1 diabetes' introduces a dynamic risk score based on microRNAs, which are tiny molecules in the blood that reflect changes in the body, including early stress in insulin-producing Beta cells. By analysing data from over 2,800 participants, the researchers found that these molecular signals could identify individuals at high risk of developing T1D long before symptoms appear. Dr. Ammira Akil, principal investigator at Sidra Medicine and director of the Metabolic and Mendelian Disorders Translational Programme, who designed the study, said: 'This study marks a significant advancement in the way we understand and manage autoimmune diseases like Type 1 Diabetes. By combining microRNA profiling with artificial intelligence, we have developed a predictive risk score that can help identify individuals at highest risk, optimise treatment decisions and determine when to intervene. It is a powerful example of how AI and Machine Learning are transforming precision medicine into real-world clinical impact.' Sidra Medicine's contribution to the study was led by the Mendelian and Metabolic Translational Research Programme under the Precision Genomics and Translational Omics Lab. The team played a keyrole in the early laboratory work on primary human insulin-producing cells and conducted critical analyses that helped with the development and validation of the clinical risk score. The study findings complement ongoing efforts at Sidra Medicine, including the DANNA1 cohort, a local foundational population-based registry of individuals with T1D in Qatar that underpin the upcoming national screening programme for early detection and prevention of Type 1 Diabetes. Prof. Khalid Fakhro, chief research officer and chair of the Precision Medicine Programme at Sidra Medicine, said: 'The study findings demonstrate that the microRNA-based dynamic risk score can accurately differentiate between individuals with and without Type 1 Diabetes. It also predicts who may become insulin dependent after an islet cell transplant and identifies patients likely to respond to specific therapies - insights that current clinical markers cannot provide. 'Importantly, this assessment is achievable through a simple, minimally invasive blood test, making it highly promising for routine clinical use. The study also reflects our ongoing commitment to advancing the use of artificial intelligence as a powerful tool to drive earlier diagnosis, more precise treatments, and safer outcomes for patients.' The next phase of the research will focus on validating the findings across broader and more diverse populations and assessing the integration of the dynamic risk score into clinical trials and early intervention strategies. Sidra Medicine will continue to support these efforts through its research programmes and ongoing collaborations. The groundbreaking study was made possible through a multinational collaboration involving experts from Sidra Medicine, Breakthrough T1D, the University of Western Sydney, and the PREDICT T1D Study Group.
